Tag Archive for: women’s health

To coincide with National Women’s Health Week, Health@WPP, WPP’s health community serving clients across the healthcare sector, is expanding its commitment to better reflect women’s health issues and real-life experiences in marketing.    

Veozah, an oral once-daily medication, is the first FDA-approved NK3 receptor antagonist for hot flashes, a common symptom of menopause that can affect health and quality of life.

The joint committee of external experts voted unanimously in favor of Perrigo, finding that the benefits of allowing non-prescription use of the birth control tablet Opill outweigh its risks.

The U.S. health regulator’s reviewers on Friday raised concerns around allowing Perrigo Co’s birth control drug over the counter, saying switching to non-prescription sale could lead to inappropriate usage by consumers.

The U.S. Supreme Court is poised to determine whether the abortion pill mifepristone will continue to be broadly available in the United States as it weighs a bid by Democratic President Joe Biden’s administration to defend the drug in a challenge to its regulatory approval by anti-abortion groups.

Use of the drug misoprostol on its own to terminate pregnancies is on the rise in the United States as providers seek a preemptive alternative while a ban on abortion pill mifepristone is being considered in court.

President Joe Biden’s administration on Friday asked the U.S. Supreme Court to block limits set by lower courts on the abortion pill mifepristone as the federal government seeks to defend access to the drug in the face of mounting abortion bans and restrictions enacted by Republican-led states.

The panel will decide on recommending the non-estrogen contraceptive as a daily OTC birth control pill on May 9 and 10. The drug, Opill, is expected to be the first such pill in the United States if approved.

The company said the focus of its drug research would shift away from women’s health, a traditional pillar of Germany’s largest drugmaker, to hone in on neurology, rare diseases and immunology.

In addition to job cuts, the company slashed the CEO’s pay by 40%.